A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC

A single-center phase Ib/II dose escalation and dose-expansion clinical trial of REGN5678 plus cemiplimab

Trial Details

NCT ID
NCT06826768
Phase
PHASE1
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • REGN5678
  • Cemiplimab
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Men .18 years of age.
  • Histologically or cytologically confirmed adenocarcinoma of the prostate without pure small cell carcinoma.
  • mCRPC with disease progression after at least two lines of systemic therapy, including one line of second-generation anti-androgen therapy, accordi…
  • PSA progression as defined by a rising PSA level confirmed with an interval of \>1 week between each assessment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →